Nanoformulation of a novel chemotherapy agent for intended application for the therapy of pancreatic cancer patients
Parole chiave NANOFORMULATION, ALBUMIN, TUBULIN, COLCHICINE
Riferimenti JACEK ADAM TUSZYNSKI
Riferimenti esterni Prof. Afsaneh Lavasanifar, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada
Gruppi di ricerca 28- biomedica
Descrizione A novel colchicine derivative, called CCI-001, has been extensively tested against numerous cancer cell lines with very encouraging results. One of the potential applications of this compound could be pancreatic cancer. Currently, a nano-formulated paclitaxel molecule with the use of albumin as a delivery vehicle has been very successfully applied for. pancreatic cancer chemotherapy. This construct has been called nab-paclitaxel (Abraxane). In this project, we will attempt to use a similar method to formulate and test the new compound CCI-001. Most of this work will be performed in the lab of Prof. Lavasanifar at the University of Alberta. Edmonton, Canada.
Conoscenze richieste nanoformulation, basics of pharmacology, nano-bioengineering
Scadenza validita proposta 01/11/2020 PROPONI LA TUA CANDIDATURA